Amgen Inc. (AMGN)

Amgen's stock price has experienced some fluctuations in the past six months. As of July 18, 2025, the share price was $294.76, representing a decline of 12.27% over the past year. However, in the last six months, the stock has moved up by 7.25%. A notable event impacting the stock was a 6% fall on Monday, June 23, 2025, after mid-stage clinical trial results for its experimental obesity drug, MariTide, revealed a need for a low starting dose. Despite this, Amgen's stock has shown a 1.27% rise over the last month and an 8.51% rise over the last six months. Analysts currently have a "Hold" consensus rating for AMGN stock, with a 12-month price target of $322.85, indicating a potential upside.

Information regarding specific demand seasonality for Amgen's products and services is not explicitly detailed. However, the company's free cash flow has been on a relatively stable upward trend, driven by an increase in demand for its products as the occurrence of chronic illnesses rises. The biotechnology industry, being highly regulated, also limits the number of new entrants, which can contribute to more stable demand for established players like Amgen. Additionally, the seasonality profile for Amgen Inc. stock price shows that July has historically closed higher than June in 76.74% of the previous 42 Julys, suggesting a potential positive seasonal trend for the stock.

Amgen Inc., founded in 1980 and headquartered in Thousand Oaks, California, is a multinational biopharmaceutical company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics, primarily protein-based medications. The company leverages advanced science and technology, including AI and generative biology, to address areas of high unmet medical need within the biotechnology industry. Amgen's product portfolio caters to key therapeutic areas, including oncology/hematology, inflammation, bone health, cardiovascular disease, nephrology, and neuroscience. Major products include Prolia and XGEVA for bone diseases, Enbrel for autoimmune diseases, Repatha for hyperlipidemia, Otezla for plaque psoriasis and psoriatic arthritis, Kyprolis for multiple myeloma, Neulasta and Neupogen as immunostimulators, Aranesp for anemia, Nplate for immune thrombocytopenia, Evenity for osteoporosis, Vectibix for colorectal cancer, Blincyto for acute lymphoblastic leukemia, Tepezza for thyroid eye disease, Krystexxa for chronic refractory gout, Aimovig for migraine headaches, Lumakras for KRAS mutations, Tezspire for severe asthma, and biosimilars like Amjevita, Mvasi, Kanjinti, and Riabni.

Amgen has a significant global presence, operating in approximately 100 countries and regions worldwide. The company's revenue from the United States market has shown strong growth, particularly between 2023 and 2024. Revenue from the Rest of the World segment has also displayed consistent growth, indicating steady expansion in international markets.

Amgen maintains a strong brand reputation as a leading biotechnology pioneer, recognized for its commitment to research and innovative drug development. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes. The company's focus on developing innovative biologic therapies for serious, chronic illnesses has shaped its portfolio and market position. Amgen acquired Horizon Therapeutics in October 2023, specializing in drugs for rare diseases. The MariTide clinical trial results led to a stock price drop and scrutiny, but Amgen has highlighted progress around MariTide and other drugs. Amgen has continued to announce positive data from clinical trials for various drugs, such as the Phase 3 FORTITUDE-101 clinical trial and MariTide demonstrating up to 20% average weight loss in a Phase 2 study.

Amgen's ownership is predominantly held by institutional investors, reflecting its status as a major player in the biopharmaceutical industry. Approximately 54.34% of the company's stock is owned by Institutional Investors, 0.19% by Insiders, and 45.48% by Public Companies and Individual Investors. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., State Street Corp., Capital World Investors, Morgan Stanley, Capital International Investors, Geode Capital Management, Llc, Primecap Management Co/ca/, Charles Schwab Investment Management, Inc., and UBS Asset Management AG.